SCHEMBL192403

SCHEMBL192403

CC(C)(C)OC(=O)[C@@](N)(C(=O)OCc1ccccc1)c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.50
LTA4H P09960 2/20 0.49
PARP10 Q53GL7 1/20 0.47
PRKCA P17252 1/20 0.46
PRKCD Q05655 1/20 0.46
NR4A2 P43354 2/20 0.46
RXRA P19793 1/20 0.46
RXRB P28702 1/20 0.46
NR4A1 P22736 1/20 0.46
NR4A3 Q92570 1/20 0.46
ALDH1A1 P00352 2/20 0.44
NR1H4 Q96RI1 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.44
KMT2A Q03164 1/20 0.44
LAP3 P28838 1/20 0.44
LMNA P02545 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
PPARG P37231 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2574959 0.90 LTA4H (0.49) MAOBLTA4HPARP10NR4A2RXRA
SCHEMBL4689225 0.89 LMNA (0.46) ALDH1A1KMT2ALMNAL3MBTL1SLC6A2
SCHEMBL9042229 0.89 LMNA (0.46) ALDH1A1KMT2ALMNAL3MBTL1SLC6A2
SCHEMBL3379309 0.86 SMN1; SMN2 (0.41) ALDH1A1MEN1KMT2AL3MBTL1SLC6A2
SCHEMBL4688233 0.85 PTPN1 (0.41) LTA4HALDH1A1MEN1KMT2A
SCHEMBL193277 0.83 KDM4E (0.44) MAOBLTA4HPARP10NR4A2RXRA
SCHEMBL9043198 0.83 KDM4E (0.40) LTA4HALDH1A1KDM4EMEN1KMT2A
SCHEMBL9043111 0.83 KDM4E (0.40) LTA4HALDH1A1KDM4EMEN1KMT2A
SCHEMBL9691305 0.83 KDM4E (0.40) LTA4HALDH1A1KDM4EMEN1KMT2A
SCHEMBL27574390 0.81 MAOB (0.48) MAOBLTA4HPARP10PRKCAPRKCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1877366-B1 HYDROXAMIC ACID DERVICATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY CHROMA THERAPEUTICS LTD (GB) 2012-01-04 EP disclosed
US-7973181-B2 Hydroxamic acid derivatives as inhibitors of HDAC enzymatic activity CHROMA THERAPEUTICS LTD. (GB) 2011-07-05 US disclosed
US-20090298924-A1 HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY CHROMA THERAPEUTICS LTD (GB) 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298924-A1 HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY HDAC1, HDAC3, HAT1 MAOB 375/4885LTA4H 2416/4885PARP10 1474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.